Evelo Biosciences Inc (OTCPK:EVLO)
$ 0.0005 0 (0%) Market Cap: 9,000.00 Enterprise Value: 16.70 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Evelo Biosciences, Inc. - Special Call Transcript

May 07, 2020 / 12:30PM GMT
Release Date Price: $98.4 (+2.71%)
Operator

Good morning, and welcome to Evelo conference call to discuss its efforts to develop EDP1815 for the treatment of COVID-19. (Operator Instructions) Please be advised that this call is being recorded at the company's request.

At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed.

Jessica Cotrone
Evelo Biosciences, Inc. - VP & Head of Communications

Thank you, Felicia. This morning, we issued a press release announcing our plan to evaluate EDP1815 for the treatment of COVID-19. The release, along with the slides we will be reviewing today, is available on our website at www.evelobio.com under the Investors tab.

With me today with prepared remarks are Simba Gill, Chief Executive Officer; and Duncan McHale, Chief Medical Officer. Mark Bodmer, our President of R&D and Chief Scientific Officer, is also on the line and will be available for Q&A.

Turning to Slide 2. Before we begin, I'd like to remind everyone that statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot